Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients

American Journal of Hypertension

Volumn 9, Issue 5, 1996, Pages 426-431

  Kuriyama, Satoru ^c   Hopp, Laszlo ^b   Yoshida, Hiroaki ^d   Hikita, Miho ^d   Tomonari, Haruo ^a   Hashimoto, Takao ^d   Sakai, Osamu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

^d NONE

Author keywords

Chronic renal failure; Endothelial cells; Endothelin; Erythropoietin; Renal anemia; Thrombomodulin

Indexed keywords

ENDOTHELIN 1; ERYTHROPOIETIN; THROMBOMODULIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MALE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0030027832     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(95)00444-0     Document Type: Article

References (25)

1. Casati S, Passerini P, Camprise MR, et al: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987;295:1017-1020.
2. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Eng J Med 1987;316:73-78.
3. Mayer G, Thum J, Cada EM, et al: Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988;34:525-528.
4. Muntzel M, Hannedouche T, Lacour B, et al: Erythropoietin increases blood pressure in normotensive and hypertensive rats. Nephron 1993;65:601-604.
5. Linde T, Sandhagen B, Hagg A, et al: Blood viscosity and peripheral vascular resistance in patients with untreated essential hypertension. J Hypertens 1993;11: 731-736.
6. Tomura S, Nakamura Y, Deguchi F, et al: Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing hemodialysis. Thromb Res 1990;58:413-419.
7. Takano S, Kimura S, Ohdama S, et al: Plasma thrombomodulin in health and diseases. Blood 1990;76:2024-2029.
8. Yoshida M, Kozaki M, Ioya N, et al: Plasma thrombomodulin levels as an indicator of vascular injury caused by cyclosporine nephrotoxicity. Transplantation 1990; 50:1066-1069.
9. Katoh K, Mizuno K, Hashimoto S, et al: Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 1994;54:253-259.
10. Takahashi K, Totsune K, Mouri T: Endothelin in chronic renal failure. Nephron 1994;66:373-379.
11. Tomura S, Deguchi F, Ando R, et al: Plasma thrombomodulin in primary glomerular diseases and lupus glomerulonephritis. Nephron 1994;67:185-189.
12. Shichiri M, Hirata Y, Ando K, et al: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990;15:493.
13. Tomita K, Ujiie K, Nakanishi T, et al: Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989;321:1127.
14. Ishii H, Uchiyama H, Kazama M: Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65:618-623.
15. Eschbach JW, Kelly MR, Haley NR, et al: Treatment of anemia of progressive renal failure with recombinant erythropoietin. N Engl J Med 1989;321:158-163.
16. Lim VS, DeGowin RL, Zavala D, et al: Recombinant human erythropoietin treatment in predialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989;110:108-114.
17. Stone WJ, Graber SE, Krantz SB, et al: Treatment of the anemia of pre-dialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. Am J Med Sci 1988;296:171-179.
18. Lim VS, Fangman J, Flanaghan J, et al: Effect of recombinant human erythropoietin on renal function in humans. Kidney Int 1990;37:131-136.
19. Garcia DL, Anderson S, Rennke HG, et al: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 1988;85:6142-6146.
20. Anagnoustou A, Liu Z, Steiner M, et al: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-3978.
21. Carlini RG, Dusso AS, Obialo CI, et al: Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993;43:1010-1014.
22. Carlini RG, Reyes AA, Rothstein M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995;47:740-745.
23. Lebel M, Grose JH, Kingma I, et al: Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy. Clin Exp Hypertens 1994;16:565-575.
24. Bommer J, Alexiou C, Muller-Buhl J, et al: Recombinant human erythropoietin tharapy in haemodialysis patients - dose determination and clinical experience. Nephrol Dial Transplant 1987;2:238-242.
25. Ono K and Hisasue Y: The rate of increase in hematocrit, humoral vascoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Clin Nephrol 1992;37:23-27.